RGCC was developed by a Swiss company. It doesn't appear to yet be approved by the US Clinical Laboratory Improvement Amendments (CLIA) and The College of American Pathologists (CAP). US labs that provide medical grade testing are CLIA certified and CAP accredited. This ensures test results meet and exceed industry standards for clinical laboratory testing.

RGCC looks promising and is similar to the Galleri test. The Galleri test is a blood test, offering a new way to screen for cancers. Many cancers can start to grow but show no symptoms until later stages. With Galleri pathologists are able to look for a signal shared (tumor DNA in a person’s circulation) for more than 50 types of cancer. If a cancer signal is found, the results predict where in the body the cancer may be located to help your provider guide your next steps. Galleri should be done in addition to, not in place of, any annual cancer screenings recommended by your healthcare provider. This test does not detect all cancers and is not meant to replace genetic testing for those at increased risk of hereditary cancers.

More information can be found at https://www.galleri.com/

Patients interested in this Galleri test can talk to their primary care provider. This test is available at Mayo Clinic.